Brief: Valneva Q1 Revenue EUR 49.2 Million
07/05/2025 06:06
May 7 (Reuters) - Valneva SE VLS.PA: Q1 REVENUE EUR 49.2 MILLION Q1 NET INCOME EUR -9.2 MILLION Q1 ADJUSTED EBITDA EUR -600 THOUSAND EXPECTS PRODUCT SALES TO REACH €170-180 MILLION IN 2025 2025 FINANCIAL OUTLOOK CONFIRMED HOLDS €153 MILLION IN CASH AS OF MARCH 31, 2025 Source text: ID:nGNE7c5zl2 Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency